Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling

SIMPLE SUMMARY: Classic Hodgkin lymphoma (cHL) patients refractory to standard ABVD chemo-therapy are known to have a dismal prognosis. This has led to the hypothesis that ABVD treatment-sensitive and ABVD treatment-refractory tumours are biologically distinct. In this study, cHL patients refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Honoré, Bent, Andersen, Maja Dam, Wilken, Diani, Kamper, Peter, d’Amore, Francesco, Hamilton-Dutoit, Stephen, Ludvigsen, Maja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750842/
https://www.ncbi.nlm.nih.gov/pubmed/35008410
http://dx.doi.org/10.3390/cancers14010247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750842/
https://www.ncbi.nlm.nih.gov/pubmed/35008410
http://dx.doi.org/10.3390/cancers14010247

Ejemplares similares